Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Supportive Care and Symptom Management

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Toshihide Yokoyama

Citation

Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265

Authors

T. Yokoyama1, K. Ninomiya2, I. Oze3, T. Hata1, A. Tanaka1, A. Bessho4, S. Hosokawa4, S. Kuyama5, K. Kudo5, T. Kozuki6, D. Harada6, M. Yasugi7, T. Murakami8, M. Nakanishi9, N. Takigawa10, K. Katsui11, Y. Maeda2, K. Hotta12, K. Kiura13

Author affiliations

  • 1 Department Of Respiratory Medicine, Kurashiki Central Hospital, 700-8602 - Kurashiki/JP
  • 2 Department Of Hematology, Oncology And Respiratory Medicine,, Okayama University Graduate School of Medicine, 700-0005 - Okayama/JP
  • 3 4. division Of Epidemiology And Prevention, Aichi Cancer Center, Nagoya/JP
  • 4 Department Of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama/JP
  • 5 Department Of Respiratory Medicine, NHO Iwakuni Medical Center, Iwakuni/JP
  • 6 Department Of Thoracic Oncology And Medicine, NHO Shikoku Cancer Center, Matsuyama/JP
  • 7 Department Of Respiratory Medicine, Chugoku Central Hospital, Fukuyama/JP
  • 8 Department Of Respiratory Medicine, Onomichi Municipal Hospital, Onomichi/JP
  • 9 Depertment Of Medical Oncology, NHO Yamaguchi-Ube Medical Center, Ube/JP
  • 10 Depertment Of General Internal Medicine 4, Kawasaki Medical School, Okayama/JP
  • 11 Department Of Radiology, Okayama University Graduate School of Medicine, 700-0005 - Okayama/JP
  • 12 Center Of Innovative Clinical Medicine, Okayama University Hospital, 700-0005 - Okayama/JP
  • 13 Department Of Respiratory Medicine, Okayama University Hospital, 700-0005 - Okayama/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1483

Background

Sodium alginate, which has been approved for treatment of gastritis in Japan, is highly viscous and thus remains in the esophageal mucosa for long periods, leading to a protective effect in the esophagus. The purpose of this trial was to investigate whether sodium alginate has a substantial preventive effect on severe esophagitis in pts with non-small-cell lung cancer (NSCLC) receiving concurrent chemoradiotherapy (CRT).

Methods

Patients with untreated stage III NSCLC who were eligible for concurrent CRT were randomly assigned at a 1:1:1 ratio to receive one of the following treatments: sodium alginate administered concomitantly with CRT (A), sodium alginate administered soon after development of extremely mild esophagitis during CRT (B), or water administered with CRT (C). The primary endpoint was the proportion of pts with G3 or higher severe esophagitis (CTCAE ver. 4.0).

Results

Ninety-four patients were randomly assigned to the three treatment arms between Feb 2014 and Sep 2018. The study was prematurely terminated in Oct 2018 because of slow accrual. The proportion (95% confidence interval) of patients with G3 or more severe esophagitis was 12.5% (3.5–29.0%) in arm A, 9.8% (2.0–25.8%) in arm B, and 19.4% (7.5–37.5%) in arm C. Fewer patients receiving sodium alginate had onset of G3 esophagitis, but the differences compared with arm C were not significant (A v C: p = 0.46; B v C: p = 0.28). The rate of non-hematologic toxicities other than esophagitis was 29% in arm A, 26% in arm B, and 43% in arm C. Of note, early use (arm A) but not late use (arm B) of sodium alginate resulted in a significantly lower rate of febrile neutropenia (FN) compared with arm C (A v C: 3.1% v 19.4%, p = 0.04; B v C: 6.5% v 19.4%, p = 0.13). The 2-year progression-free and overall survival rates were 36% and 78% in arm A, 52% and 90% in arm B, and 61% and 75% in arm C, respectively.

Conclusions

Sodium alginate did not show a significant preventative effect on radiation-induced severe esophagitis in patients with NSCLC. However, its early use resulted in a lower rate of FN onset induced by CRT, suggesting that esophageal mucosal protection by sodium alginate may suppress FN.

Clinical trial identification

UMIN 000013113.

Editorial acknowledgement

Legal entity responsible for the study

Okayama Lung Cancer Study Group.

Funding

Has not received any funding.

Disclosure

T. Yokoyama: Honoraria (self): Chugai Pharmaceutical co ltd; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): MSD KK; Honoraria (self): AstraZeneca; Honoraria (self): Ono Pharmaceutical co Ltd. K. Ninomiya: Honoraria (self): Lilly Japan; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): AstraZeneca; Honoraria (self): Ono Pharmaceutical co ltd; Honoraria (self): Chugai Pharmaceutical co ltd; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): MSD KK. A. Bessho: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Astellas Pharma; Honoraria (self): Novartis; Research grant / Funding (self): Kyorin; Research grant / Funding (self): Amgen; Research grant / Funding (self): Taisho Toyama Pharma; Research grant / Funding (self): Bayer Yakuhin. S. Hosokawa: Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self): Ono Pharmaceutical; Honoraria (self): AstraZeneca. T. Kozuki: Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Lilly Japan; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Japan; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): MSD KK; Research grant / Funding (institution): Merck Serono. D. Harada: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): AstraZeneca; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): MSD KK; Honoraria (self): Eli Lilly Japan. T. Murakami: Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): AstraZeneca. N. Takigawa: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Daiichi-Sankyo Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer-Ingelheim; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self): MSD KK; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Nippon Kayaku. K. Hotta: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self): Nippon Kayaku; Honoraria (self): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Japan; Honoraria (self), Research grant / Funding (institution): Lilly Japan; Honoraria (self), Research grant / Funding (institution): MSD KK; Research grant / Funding (institution): Astellas Pharma. K. Kiura: Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Nippon Kayaku; Honoraria (self): Daiichi Sankyo; Honoraria (self): Shionogi; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Lilly Japan. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.